What are the pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in healthy elderly subjects?
Single doses of rivaroxaban up to 40 mg show predictable pharmacokinetics and are well tolerated in healthy elderly subjects.
Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in healthy elderly subjects. Adverse events were somewhat elevated in the 50 mg group, but given the small sample size, no specific conclusions can be drawn about this dosing level.
Kubitza et al. (Tue,) studied this question.